These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7689459)

  • 1. Fluoroquinolones in the treatment of cystic fibrosis.
    Høiby N; Pedersen SS; Jensen T; Valerius NH; Koch C
    Drugs; 1993; 45 Suppl 3():98-101. PubMed ID: 7689459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of ciprofloxacin in the treatment of patients with cystic fibrosis.
    van den Broek PJ; Bakker W; Mattie H; van Gulpen C
    Pharm Weekbl Sci; 1987 Dec; 9 Suppl():S68-71. PubMed ID: 3438152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Jensen T; Pedersen SS; Nielsen CH; Høiby N; Koch C
    J Antimicrob Chemother; 1987 Oct; 20(4):585-94. PubMed ID: 3479420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.
    Stockmann C; Sherwin CM; Zobell JT; Young DC; Waters CD; Spigarelli MG; Ampofo K
    Pediatr Pulmonol; 2013 Mar; 48(3):211-20. PubMed ID: 22949224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal.
    LeBel M
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):316-24. PubMed ID: 1907546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
    Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The use of ofloxacin in cystic fibrosis patients].
    Romano L; Girosi D; Spallone E; Parisi F; Minicucci L; Romano C
    Minerva Pediatr; 1992 Mar; 44(3):79-86. PubMed ID: 1518497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.
    Guillot E; Sermet I; Ferroni A; Chhun S; Pons G; Zahar JR; Jullien V
    Pharmacotherapy; 2010 Dec; 30(12):1252-8. PubMed ID: 21114393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis.
    Goldfarb J; Stern RC; Reed MD; Yamashita TS; Myers CM; Blumer JL
    Am J Med; 1987 Apr; 82(4A):174-9. PubMed ID: 3555032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Activity of fluoroquinolones studied on a model of suppurative meningoencephalitis caused by Pseudomonas aeruginosa in mice].
    Padeĭskaia EN; Mnatsakanian VE
    Antibiot Khimioter; 1991 Jul; 36(7):25-8. PubMed ID: 1953184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of ciprofloxacin in children with cystic fibrosis.
    Orenstein DM; Pattishall EN; Noyes BE; Kurland G; Hartigan ER; Yu VL
    Clin Pediatr (Phila); 1993 Aug; 32(8):504-6. PubMed ID: 8403750
    [No Abstract]   [Full Text] [Related]  

  • 13. The impact of fluoroquinolones use on antibiotic resistance in an intensive care burn department.
    Thabet L; Memmi M; Turki A; Messadi AA
    Tunis Med; 2010 May; 88(5):297-300. PubMed ID: 20517823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
    Fernández-Olmos A; García-Castillo M; Maiz L; Lamas A; Baquero F; Cantón R
    Int J Antimicrob Agents; 2012 Aug; 40(2):173-6. PubMed ID: 22727530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
    Roveta S; Schito AM; Marchese A; Schito GC
    Int J Antimicrob Agents; 2005 Nov; 26(5):366-72. PubMed ID: 16216467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fluoroquinolones--a new and important group of antimicrobial agents].
    Sander J
    Tidsskr Nor Laegeforen; 1992 Jan; 112(3):346-9. PubMed ID: 1553674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
    Hansen CR; Pressler T; Høiby N
    J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ciprofloxacin therapy in cystic fibrosis.
    Scully BE; Nakatomi M; Ores C; Davidson S; Neu HC
    Am J Med; 1987 Apr; 82(4A):196-201. PubMed ID: 3555036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis.
    Shalit I; Stutman HR; Marks MI; Chartrand SA; Hilman BC
    Am J Med; 1987 Apr; 82(4A):189-95. PubMed ID: 3555035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative efficacy and safety of ciprofloxacin, ofloxacin, and pefloxacin in treatment of respiratory infections in children with cystic fibrosis].
    Postnikov SS
    Antibiot Khimioter; 2001; 46(3):16-20. PubMed ID: 11548276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.